Δ<sup>9</sup>-tetrahydrocannabinol treatment improved endothelium-dependent relaxation on streptozotocin/nicotinamide-induced diabetic rat aorta by Altınok, A. et al.
0231–424X/$ 20.00 © 2015 Akadémiai Kiadó, Budapest
Acta Physiologica Hungarica, Volume 102 (1), pp. 51–59 (2015) 
DOI: 10.1556/APhysiol.102.2015.1.5
∆9-tetrahydrocannabinol treatment improved 
endothelium-dependent relaxation on streptozotocin/
nicotinamide-induced diabetic rat aorta
A Altınok1, ZM Coşkun2, K Karaoğlu3, S Bolkent4, AG Akkan3, S Özyazgan3
1Fifth Specialty Board of Forensic Medicine Institution, Istanbul, Turkey 
2Health Services Vocational School, Istanbul Bilim University, Istanbul, Turkey 
3Deparment of Medical Pharmacology, Cerrahpaşa Medical Faculty, Istanbul University, Istanbul, Turkey 
4Department of Medical Biology, Cerrahpaşa Medical Faculty, Istanbul University, Istanbul, Turkey
Received: February 6, 2014 
Accepted after revision: July 22, 2014
Objective: In this study, we investigated the possible effect of ∆9-tetrahydrocannabinol (THC), a peroxisome 
proliferator-activated receptor gamma (PPARγ) agonist, on metabolic control and vascular complications of diabetes 
in streptozotocin/nicotinamide (STZ/NIC) induced type 2 diabetes mellitus. Material and methods: Type 2 diabetes 
was induced with 65 mg/kg STZ, 15 minute later 85 mg/kg NIC was given intraperitoneally (i.p.) to rats. Three days 
after diabetes induction, THC (3 mg/kg/day, i.p.) was given for 7 days to diabetic rats. Body weight and plasma 
glucose levels of rats were measured in all groups before and at the end of 3 weeks after diabetes induction. 
Acetylcholine (Ach) and sodium nitroprusside (SNP) potency and maximum relaxant effects were calculated on 
aortic rings pre-contracted with noradrenaline (NA). Results: At the end of 3 weeks, blood glucose levels of diabetic 
group significantly increased in comparison with the control group. Increased plasma glucose levels were 
significantly decreased by the treatment of THC. Ach induced relaxation was impaired whereas endothelium-
independent relaxation to SNP was unaffected on isolated diabetic rat aorta. THC treatment enhanced Ach induced 
relaxation on diabetic rat aortas. Discussion: These results suggested that THC improved endothelium-dependent 
relaxation in STZ/NIC induced diabetic rat aorta and that these effects were mediated at least in part, by control of 
hyperglycemia and enhanced endothelial nitric oxide bioavailability.
Keywords: rat, aorta, ∆9-tetrahydrocannabinol, type 2 diabetes mellitus, STZ/NIC induced diabetes, endothelial 
dysfunction
Type 2 diabetes mellitus comprises an array of dysfunctions resulting from the combination 
of resistance to insulin and inadequate insulin secretion. These disorders are characterized by 
hyperglycemia and associated with microvascular and macrovascular complications. In both 
diabetic patients and animal models, endothelial dysfunction is asserted to have a key role in 
the progression of macro- and microangiopathy (5, 33).
The most psychoactive substance in cannabis is ∆9-tetrahydrocannabinol (THC) and its 
derivatives have recently taken interest for researchers because of the possible therapeutic 
use in diabetes. Although the evidence regarding the effects of cannabis on diabetes is 
complex, ranging from anecdotal reports on benefits and harms to experimental research on 
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cannabinoids (7). In vitro studies have shown that THC can be useful in diabetes treatment 
via increasing insulin secretion (20), insulin sensitivity (10) and its antioxidant effects (4). 
THC might have beneficial effects on diabetes, as it activates the peroxisome proliferator-
activated receptor-γ (PPARγ) (25). PPARγ is a ligand-activated transcription factor, belonging 
to the nuclear receptor superfamily and is a regulator of lipid and glucose metabolism (29). 
PPARγ agonists improve insulin sensitivity, cause vasorelaxation and increase nitric oxide 
bioavailability; besides these, it also has anti-inflammatory effects. Because of these 
properties, it is one of the options for treating diabetes and avoiding possible complications 
(6, 15).
It is understood that no animal model is identical to any human disease; none of the 
available animal models of type 2 diabetes mellitus exactly simulate the human type 2 
diabetes mellitus. However, streptozotocin/nicotinamide (STZ/NIC) rat models have several 
advantages over the other models and are considered to be one of the suitable experimental 
animal models for type 2 diabetes mellitus. For that reason, we used STZ/NIC combination 
in adult rats to generate type 2 diabetes modeling (19, 27).
In previous studies, it was shown that administration of THC affected the vascular 
activity in rat aorta (25). However, there is no published data regarding the effect of in vivo 
administration of THC on vascular activity of diabetic rat aorta. 
The aim of this study was to investigate the effect of THC treatment on the vascular 
activity of STZ/NIC induced diabetic rat aorta.
Materials and Methods
Animals
Male Sprague-Dawley rats (8–10 weeks) were randomly divided into four groups. Each 
group consisted of 6 rats. THC was imported by the permission (permit no. 2010/80) of 
the Drugs Department of Turkey Republic, Ministry of Health, General Directorate of 
Pharmaceuticals and Pharmacy. The experimental procedures were approved (approval no: 
2012/94) by Animal Ethical Committee of the Istanbul University. The first group (control 
group) received physiological saline solution, i.p. for 7 days. The second group comprised of 
STZ/NIC induced diabetic control rats. Diabetes was induced by a single i.p. dose of 65 mg/
kg streptozotocin (STZ), 15 minute after the administration of 85 mg/kg, i.p. nicotinamide 
(NIC). STZ and NIC were freshly prepared in saline solution. Plasma glucose levels were 
determined by using tail vein blood samples (Accu-check, Roche Diagnostics), 72 h after the 
STZ/NIC injection. Rats with glucose concentration of 200 mg/dl or higher were considered 
as diabetic. The third group was the THC-treated group (3 mg/kg/day, i.p for 7 days), and the 
fourth group was the THC-treated diabetic group. Three days after the diabetes induction, 
THC (3 mg/kg/day, i.p.) was given for 7 days in the diabetic group. Body weight and plasma 
glucose of rats were measured in all groups before and at the end of 3 weeks after diabetes 
induction. All rats were kept under identical conditions for 3 weeks with free access to food 
and water. 
Drugs
THC was provided by Lipomed THC-135-100LE. STZ used in the experiments was obtained 
from Sigma Chemical (St. Louis, MO, USA) and other chemicals were obtained from Merck 
(Darmstadt, Germany).
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Experimental design
The rats were anestethetized with sodium thiopenthal, on day 15 following the last 9-THC 
injections. After sacrifice, the thoracic aorta was rapidly removed and placed into Krebs–
Henseleit solution (KHS, nM: NaCL 119, KCL 4.70, MgSO4.7H20 1.20, KH2PO4 1.20, CaCl2 
2.50, NaHCO3 25, Glucose 11.1), cut into 3–4 mm aorta rings and was mounted with a 
resting tension of 1 g in an isolated organ bath (Ugo-basile, 4050, Italy) containing 25 ml 
KHS, aerated (95% O2 and 5% CO2) at 37 oC. The responses of isolated organs were recorded 
isometrically using a force-displacement transducer (BİOPAC MP36, USA) integrated Tissue 
Bath System (Commat, Ankara, Turkey). Following a one-hour incubation period, 
concentration-response relationships of the aorta were obtained with doses of noradrenaline 
(NA). NA (10–9–10–4 mol/l) was added in a cumulative manner until a maximal response was 
achieved. After the addition of each dose, a plateau response was obtained before the addition 
of a subsequent dose. A cumulative relaxation curve to acetylcholine (Ach) (10–9–10–4 mol/l) 
was obtained in each strip pre-contracted submaximally (EC90 10–5) by addition of NA. 
A cumulative relaxation curve to sodium nitroprusside (SNP) (10–9–10–4 mol/l) was obtained 
for each strip pre-contracted submaximally (approx. EC90 10–5 mol/l) by addition of NA. At 
the end of each experiment, the tissue was blotted dry, measured and weighed.
Statistical analysis
All isolated organ responses were expressed as apparent affinity constant (pD2) and percentage 
of corresponding maximal responses to each agonist (Emax for NA and % Inh.max. for Ach.). 
Contractile responses to noradrenaline were calculated as the increase in tension in milligrams, 
in response to agonist per milligram of aorta (mg tension / mg wet weight). The statistical 
analyses were performed by one-way ANOVA, followed by Tukey’s multiple comparison 
tests for isolated-organ bath experiments. The statistical analyses were carried out using 
SPSS version 11.0 and Microsoft Office Excel. The values were expressed as the mean ± 
SEM to show variation in groups. p < 0.05 was considered statistically significant.
Results
General characteristics of animals 
Body weight and blood glucose levels for four groups are shown in Table I. Body weight of 
rats did not change initially and even after three weeks in any of the groups. THC treatment 
did not affect the final weight of rats. 
As indicated in Table I, plasma glucose levels were significantly elevated in diabetic rats 
(409.71 ± 29.12 mg/dl) in comparison with control rats (106.83 ± 2.75 mg/dl, p < 0.05). The 
increase in plasma glucose levels were significantly decreased by the treatment with THC 
(298.17 ± 40.18 mg/dl, p < 0.05).
Contractile response to noradrenaline
The contraction values, pD2 and Emax of aortic strips as a response to NA of all experimental 
groups are shown in Table III. pD2 values of NA were significantly decreased in diabetic rats 
(7.72 ± 0.10) compared with the control rats (8.15 ± 0.08, p < 0.05). THC treatment could not 
improve the decreased pD2 values of NA in diabetic rats (7.49 ± 0.05). Emax of NA did not 
change in aortic strips of all groups (Fig. 3).
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Table I. Body weight and blood glucose levels of groups
After 3 weeks
Blood glucose (mg/dl) Body weight (g)
Control 106.83 ± 2.75 214.67 ± 7.48
Diabetic 409.71 ± 29.12a 193.33 ± 12.10
THC 124.67 ± 8.56 199.25 ± 11.68
Diabetic+THC 298.17 ± 40.18a,b 189.75 ± 33.17
Values are mean ± SEM, a p < 0.05 compared to the control and b p < 0.05 compared to the diabetic group.  
Plasma glucose levels were elevated in STZ/NIC-induced type 2 diabetes and decreased by the treatment of THC. 
THC treatment did not affect the body weight of STZ/NIC-induced type 2 diabetic rats
Table II. pD2 and Inh.max. % values for Ach and SNP-induced relaxations of aortic rings of groups
Ach SNP
Inh.max. % pD2 Inh.max. % pD2
Control 88.30 ± 6.06 7.73 ± 0.26 92.61 ± 3.04 8.93 ± 0.16
Diabetic 52.97 ± 6.32a 6.34 ± 0.18a 98.67 ± 2.30 8.40 ± 0.23
THC 80.78 ± 2.79 7.38 ± 0.17 97.25 ± 2.99 8.27 ± 0.20
Diabetic+THC 73,94 ± 3,18ab 7.48 ± 0.18b 101.31 ± 3.99 8.34 ± 0.10
Values are mean ± SEM, a p < 0.05 compared to the control and b p < 0.05 compared to the diabetic group.  
Sensivity (pD2) and Maximum Relaxation (Inh.max. %) of Ach were decreased on the STZ/NIC-induced type 2 
diabetic group and improved with THC treatment
Table III. pD2 and Emax values (mg / mg ww) for NA-induced contraction of aortic rings from groups
NA-Emax NA-pD2
Control 258.58 ± 29.42 8.15 ± 0.08
Diabetic 256.58 ± 28.60 7.72 ± 0.10a
THC 284.86 ± 54.03 8.16 ± 0.15
Diabetic+THC 311.73 ± 31.29 7.49 ± 0.05a
Values are mean ± SEM, a p < 0.05 compared to the control and b p < 0.05 compared to the diabetic group.  
Sensivity (pD2) of NA were decreased on the STZ/NIC-induced type 2 diabetic and THC-treated  
STZ/NIC-induced diabetic rat aorta
Vascular relaxation
Endothelium-dependent relaxation values as a response to Ach (pD2, and Inh.max. %) of aortic 
strips pre-contracted with NA (submaximally, approx. EC90), are summarized in Table II. 
pD2 of Ach were decreased in the diabetic rats (pD2 = 6.34 ± 0.18, p < 0.05) compared with 
the control rats (pD2 = 7.73 ± 0.26) and were improved in THC-treated diabetic rats (pD2 = 
7.48 ± 0.18, p < 0.05). Inh.max. % of Ach (Inh.max.% = 52.97 ± 6.32, p < 0.05) were decreased 
in the diabetic rats compared to those values of control rats (Inh.max.% = 88.30 ± 6.06) and 
they were improved in THC-treated diabetic rats (Inh.max.% = 73.94 ± 3.18, p < 0.05) (Fig. 1).
pD2 and Inh.max. % of SNP did not change in aortic strips in any of the groups (Table II 
and Fig. 2).
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Fig. 1. Acetylcholine (Ach) concentration-response curves in noradrenaline (NA, 10–6M)-precontracted rat aorta 
rings. Diabetes decreased relaxation responses to Ach and treatment with THC improved it. *p < 0.05 compared 
to the control, *†p < 0.05 compared to the diabetic group. Each point is the mean ± SEM of experiments
Fig. 2. Sodium nitroprusside (SNP) concentration-response curves in noradrenaline (NA, 10–6M)-precontracted rat 
aorta rings. Neither diabetes nor treatment with THC affected relaxation responses to SNP. Each point is the  
mean ± SEM of experiments
Fig. 3. Contractile response curves of noradrenaline (NA) in rat aorta rings. Neither diabetes nor treatment with 
THC affected contraction responses to NA. Each point is the mean ± SEM of experiments
56
Acta Physiologica Hungarica 102, 2015
Altınok A et al.
Discussion
Type 2 diabetes mellitus is one of the most prevalent metabolic disorders worldwide. 
Medications in use have intended controlling blood glucose levels, hence the complications 
of the type 2 diabetes mellitus. It has been claimed that cannabis and its derivative compounds 
can be used in diabetes mellitus treatment. Therefore, major active components of cannabis 
THC have been tested for the treatment of type 2 diabetes mellitus and its vascular 
complications.
THC appears principally to exert its pharmacological action by stimulating the 
endocannabinoid system, via the cannabinoid cell-surface receptors CB1 and CB2. This 
system appears to have a role in the regulation of body weight and food intake (22).
In human studies, stimulation of CB1 receptors by THC has been shown to cause 
increased food intake, blockade of these receptors, such as by treatment with the selective 
CB1 receptor antagonist rimonabant, has been shown to have beneficial effects on diabetes, 
such as weight loss (14). However, the present study indicated that THC treatment did not 
cause weight gain in normal and diabetic rats. And this is thought to be the cause of 
administration dose and/or duration of THC.
STZ/NIC rat models have several advantages and are considered to be one of the most 
suitable experimental animal models of type 2 diabetes mellitus. For that reason, STZ/NIC 
combination was used to generate type 2 diabetes models (19).
Several studies have indicated that THC interferes in both the release of insulin and its 
action. It has been found that THC increases insulin secretion via CB1 and CB2 receptors 
(16, 20), whereas, in contrast to the above findings some studies have shown that THC 
decreases insulin secretion via CB1 receptors in pancreas and causes beta cell apoptosis 
(19, 25).
Besides, literature has also shown that THC enhances insulin action by decreasing 
TNF-α level (35) and increasing gene expression of IRS-1, IRS-2 and GLUT4 (10). PPARγ 
agonists are now widely used in the management of type 2 diabetes to improve insulin 
sensitivity (31) by increasing IRS-1, IRS-2, PKB/Akt, and GLUT4 (37). These effects on 
insulin sensitivity can be thought as THC being a PPAR gamma receptor agonist (17).
The data of the present study indicated that plasma glucose levels significantly decreased 
in THC-treated STZ/NIC-induced type 2 diabetic rats. Most of the studies about the effect of 
THC on glucose metabolism are in vitro studies done in cell culture. Our study is an in vivo 
study that shows the systemic net effect of THC on glucose metabolism, so the results can be 
extrapolated to diabetes associated with an increased risk for vascular deterioration. 
Endothelial cells regulate basal vascular tone and vascular reactivity with the release of a 
variety of contracting and relaxing factors (9). It has been shown that hyperglycemia, which 
is one of the most important symptoms of diabetes, can cause endothelial cell damage by 
several mechanisms, including apoptosis and increased reactive oxygen species formation 
(11, 30, 32).
The effects of diabetes on vascular responsiveness of the rat aorta have been widely 
studied but there are conflicting results. Although, some researchers demonstrated that the 
maximum relaxation response of Ach decreased but not the sensitivity in diabetes (28, 34). 
The results of the present study, in accordance with others (12, 15) revealed that diabetes 
decreased the maximum relaxation and the sensitivity of Ach.
In our study THC treatment enhanced the maximum relaxation (Inh.max) responses and 
the sensitivity (pD2) of Ach in diabetic rat aortas.
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Hyperglycemia is the major causal factor in the development of endothelial dysfunction 
in patients with diabetes mellitus. Controlled hyperglycemia remains the best way to improve 
endothelial function and to prevent atherosclerosis and other cardiovascular complications of 
diabetes. Because of that, THC treatment shows an improving effect on endothelial 
dysfunction in diabetic rats and is basically linked with blood glucose regulation.
In type 2 diabetes, hyperglycemia causes the production of reactive oxygen species 
(ROS) that makes oxidative injury. Also, oxidative stress plays critical roles in the development 
of diabetes complications. Recent studies have shown that the endocannabinoid system may 
significantly influence reactive oxygen species production, and subsequent tissue injury (14). 
Some studies have shown that THC acts as potent antioxidant without any cannabinoid 
receptor activation (12).
One of the PPAR gamma agonist, rosiglitazone has antioxidant effects and it increases 
NO bioavailability and catalase activity independently from blood glucose regulation (2); 
besides THC does the same effect via increasing superoxide dismutase activity (25). 
Therefore, these results show that THC might contribute to decrease the vascular complications 
of diabetes.
On the other hand, insulinotropic effect of THC (16, 20) can indirectly affect its relaxant 
response, because insulin itself may relax smooth muscle by releasing NO. 
So these findings indicate that THC improves vascular responsiveness in diabetic rat 
aortas, and these effects are mediated, at least in part, by control of hyperglycemia and 
enhanced endothelial nitric oxide bioavailability by PPAR gamma agonism (1, 18).
It is known that SNP acts through direct stimulation of vascular smooth muscle cells 
independently from an intact endothelium. Some of the previous studies claimed that SNP-
induced endothelium-independent relaxation decreased in diabetes (23). However many 
others have shown that diabetes had no effect on SNP responses (13). Our results show that 
SNP responses were not different between control and other groups. THC improved the 
endothelium-dependent response to Ach but did not change the endothelium-independent 
response to SNP.
In vitro studies have indicated that the cannabinoids have affinities to other receptors 
besides cannabinoid receptors, when applied directly into the organ bath (8, 25, 36). Among 
them is PPAR gamma receptors. It has been found that THC is a PPAR gamma ligand and 
causes vasorelaxation in isolated aorta via PPAR gamma receptors and independently from 
CB1 receptors (38).
However in present the study, the administration of THC for 3 mg/kg/day for 7 days did 
not change the maximum relaxation responses and sensitivity of Ach in non-diabetic rat 
thoracic aorta.
Previous studies showed no vasodilating effect of THC (21). It can be speculated that 
THC was administered systemically not directly into organ bath.
Many studies reported inconsistent results with increased (3, 24) or unchanged (36) 
responsiveness to NA in aortic rings of diabetic rats. The present study demonstrates that 
NA-induced maximum contraction did not change in aortic rings of diabetic rats but pD2 
values of NA were significantly decreased in diabetic rats and THC-treated diabetic rats 
compared with the control rats. Some of the previous studies (26) have claimed that 
administration of THC causes acute vasoconstriction in different arteries. But we did not see 
any vasoconstrictive effect of in vivo used THC. As discussed above, the reason of this 
difference can be that THC was not administered directly into the organ bath, but given in 
vivo to the rat. THC treatment improved the control of hyperglycemia in diabetic rats and 
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Ach-induced relaxation but did not change SNP-induced relaxation and NA-induced 
maximum contraction in diabetic rat aortic ring responses. These findings indicate that THC 
improved vascular responsiveness in diabetic rat aortas, and that these effects were mediated 
by improving hyperglycemia and at least in part, by enhanced endothelial nitric oxide 
bioavailability by PPAR gamma agonism.
In our study, we showed that THC given 3 mg/kg/day for 7 days decreased hyperglycemia 
without any weight gain in diabetic rats, and as linked to that ameliorated Ach-induced 
endothelium-dependent relaxation responses. But we also need further studies that will show 
the effects of long term and different dose usage of THC. As, we think that, in long-term 
administration, THC may increase food intake and so may result in weight gain and might 
worsen the prognosis of diabetes.
These effects suggest the possible beneficial effects of THC in in vivo experimental 
diabetes and its vascular complications.
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